ArticleFrontiers in medicine2025
Serum acylcarnitines profile at ICU discharge to predict mid-term muscle outcomes: an exploratory study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging assessment, biomarkers, and interventions: progress in muscle health research.Frontiers in rehabilitation sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alterations in acylcarnitines (AC) profile may reflect mitochondrial and metabolic disturbances after critical illness. This study investigated the association between AC profile at ICU discharge (ICUD) and muscle outcomes assessed 3 months (M3) later in survivors of a prolonged stay in ICU. Methods: Adults enrolled in our post-ICU clinic were included if they completed the ICUD assessment and attended the M3 consultation. Blood analysis was routinely performed at both time points, including AC profile. Muscle outcomes included urea/creatinine ratio, sarcopenia index, quadriceps and handgrip strengths, maximal inspiratory and expiratory pressures. Muscle health was defined arbitrarily as a composite of all these muscle parameters. Results: A total of 127 patients [age 63 (55-70) years] survived an ICU stay of 13 (8-33) days and were analysed. Free carnitine (C0) concentration was 44.4 (33-52.2) μmol/L. The total AC/C0 ratio (normal ≤ 0.4) was 0.37 (0.28-0.47). An AC/C0 ratio >0.4 was observed in 55/127 (43.3%). The short-chain and long-chain ACs reached, respectively, 1.2 (0.9-1.7) μmol/L and 0.9 (0.6-1.2) μmol/L. At M3, the urea/creatinine ratio and the sarcopenia index were, respectively, 38.3 (28.3-50.3) and 0.7 (0.6-0.9). Quadriceps strength was 2.9 (2.1-3.7) N/kg and handgrip strength was 25 (19-34) kg. In univariate analysis, none of the AC markers were associated with any of the muscle outcomes. A multifactorial linear model, including metabolic and AC markers, failed to predict M3 muscle health. Conclusion: In our exploratory cohort, AC profile as an isolated marker failed to predict post-ICU muscle weakness as assessed in daily practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.